ZONTRON BETASONE CREAM 0.1%WW

Страна: Малайзія

мова: англійська

Джерело: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Активний інгредієнт:

BETAMETHASONE

Доступна з:

TERAPUTICS SDN BHD

ІПН (Міжнародна Ім'я):

BETAMETHASONE

Одиниць в упаковці:

50 gm; 30 gm

Виробник:

TERAPUTICS SDN BHD

інформаційний буклет

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
ZONTRON BETASONE CREAM 0.1%W/W
Betamethasone Valerate (1mg/1g)
1
WHAT IS IN THIS LEAFLET
1. What Zontron Betasone Cream
0.1%w/w is used for
2. How Zontron Betasone Cream
0.1%w/w works
3. Before you use Zontron Betasone
Cream 0.1%w/w
4. How to use Zontron Betasone Cream
0.1%w/w
5. While you are using it
6. Side effects
7. Storage and Disposal of Zontron
Betasone Cream 0.1%w/w
8. Product Description
9. Manufacturer and Product
Registration Holder
10. Date of revision
WHAT
ZONTRON
BETASONE
CREAM
0.1%W/W IS USED FOR
Zontron
Betasone
Cream
0.1%w/w
is
used
for
inflammatory
condition
responding to corticosteroid therapy.
HOW
ZONTRON
BETASONE
CREAM
0.1%W/W WORKS
Zontron
Betasone
Cream
0.1%w/w
contains a medicine called betamethasone
valerate. It belongs to a group of medicine
called
corticosteroids
that
reduces
swelling and itchiness.
BEFORE
YOU
USE
ZONTRON
BETASONE
CREAM 0.1%W/W
_- When you must not use it _
Do not apply Zontron Betasone Cream
0.1%w/w if:

You are allergic (hypersensitive) to
betamethasone or to any of the other
ingredients in this medicine.
Do
not
use
Zontron
Betasone
cream
0.1%w/w for the following condition:

Untreated skin infections

Face redness

Acne

Itchiness without inflammation

Itchiness around the anus and genital

rashes around your mouth

skin conditions in infants under one
year of age, including inflammation.
_ _
_ _
_ _
_ _
_- Before you start to use it _
Pregnancy and breast feeding:

Ask your doctor or pharmacist for
advice before applying this medicine
if you are pregnant or breastfeeding.

It
is
not
known
whether
betamethasone
is
found
in
breast
milk
or
whether
it
has
a
harmful
effect in the newborn.

·If used during breastfeeding, do not
apply betamethasone valerate to the
breasts to avoid accidental ingestion
by the baby.

Inform your doctor or pharmacist if
you:

have history of allergic reaction
to corticosteroids

have psoriasis
_- Taking other medicines _
Tell your doctor or pharmaci

Характеристики продукта

PRODUCT LITERATURE
ZONTRON BETASONE CREAM 0.1%W/W
EACH G CONTAINS
Betamethasone 17-Valerate 1.215 mg
equivalent to Betamethasone 1 mg
PRESERVATIVE
Methyl Paraben 0.1% w/w
DESCRIPTION
Odourless, white soft cream
PHARMACODYNAMICS PROPERTIES
Mechanism of action
Topical
corticosteroids
act
as
anti-inflammatory
agents
via
multiple
mechanisms to inhibit late phase allergic reactions including
decreasing
the
density
of
mast
cells,
decreasing
chemotaxis
and
activation
of
eosinophils, decreasing cytokine production by lymphocytes, monocytes,
mast cells and eosinophils, and inhibiting the metabolism of
arachidonic
acid.
Pharmacodynamic effects
Topical
corticosteroids
have
anti-inflammatory,
antipruritic,
and
vasoconstrictive properties.
PHARMACOKINETICS PROPERTIES
Absorption
Topical corticosteroids can be systemically absorbed from intact
healthy
skin. The extent of percutaneous absorption of topical corticosteroids
is
determined by many factors, including the vehicle and the integrity of
the
epidermal
barrier.
Occlusion,
inflammation
and/or
other
disease
processes in the skin may also increase percutaneous absorption.
Distribution
The
use
of
pharmacodynamic
endpoints
for
assessing
the
systemic
exposure of topical corticosteroids is necessary because circulating
levels
are well below the level of detection.
Metabolism
Once absorbed through the skin, topical corticosteroids are handled
through pharmacokinetic pathways similar to systemically administered
corticosteroids.
They are metabolised, primarily in the liver.
Elimination
Topical corticosteroids are excreted by the kidneys. In addition, some
corticosteroids and their metabolites are also excreted in the bile.
INDICATION
Indicated for inflammatory condition responding to steroid therapy
RECOMMENDED DOSAGE
Apply a thin layer on the affected part 2 to 3 times a day until
complete
resolution of lesions.
ROUTE OF ADMINISTRATION
Topical
CONTRAINDICATIONS
Hypersensitivity to the active substance or any of the excipients
listed.
The following conditions should not be treated